Orchid Chemicals & Pharmaceuticals is currently trading at Rs. 66.90, up by 3.15 points or 4.94% from its previous closing of Rs. 63.75 on the BSE.
The scrip opened at Rs. 64.00 and has touched a high and low of Rs. 66.90 and Rs. 63.70 respectively. So far 204975 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 193.70 on 20-Apr-2012 and a 52 week low of Rs. 53.00 on 05-Mar-2013.
Last one week high and low of the scrip stood at Rs. 64.85 and Rs. 61.85 respectively. The current market cap of the company is Rs. 471.32 crore.
The promoters holding in the company stood at 32.42% while Institutions and Non-Institutions held 12.13% and 50.87% respectively.
Orchid Chemicals & Pharmaceuticals’ Cephalosporin API manufacturing complex located in Alathur, Chennai has successfully cleared the USFDA inspection that it went through. The facility manufactures a range of oral and sterile Cephalosporin APIs and caters to the developed markets like USA, Europe and Japan.
Orchid Chemicals & Pharmaceuticals is a pharmaceutical company engaged in development and manufacture of active pharmaceutical ingredients (APIs) and finished dosage forms. It is also engaged in research of new drugs. The company was incorporated in the year 1992 as a 100% export-oriented unit (EOU).
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1679.85 |
| Dr. Reddys Lab | 1333.05 |
| Cipla | 1305.85 |
| Zydus Lifesciences | 947.10 |
| Lupin | 2340.20 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: